[Cincinnati Children’s Hospital Medical Center] Study Points to New Strategy for TB Meningitis Care

21 July 2026

Cincinnati Children’s Hospital Medical Center news release

TB meningitis is one of the most severe forms of TB and remains extremely difficult to treat. Even with recommended antibiotics and corticosteroids, at least one in four patients dies, and many survivors experience lasting neurological injury. These poor outcomes reflect a central challenge in care. Much of the damage is driven not only by infection, but by excessive, poorly regulated inflammation in the brain.

Addressing this challenge requires not only new antibiotic therapies, but also better ways to reduce harmful inflammation in the human brain.

In a study published in Nature Communications, researchers used a coordinated multi‑model approach to identify better ways to control damaging inflammation. The team tested a range of immunomodulatory drugs as host‑directed therapies — treatments that aim to calm harmful immune responses while still allowing the body to fight TB — and identified several approved drugs, including a commonly used GLP-1 called semaglutide, that outperformed corticosteroids in reducing harmful inflammation induced during TB meningitis.

Read the full news release here.

Source: Cincinnati Children's Hospital Medical Center